"During the second quarter we continued to advance our Phase 2b Abili-T trial in secondary progressive multiple sclerosis towards completion and we are excited to approach this significant milestone in the development of our personalized immunotherapy, Tcelna," stated Neil K. Warma, President and Chief Executive Officer of Opexa. "There are only a few scheduled patient visits remaining in the study and top-line results are expected early in the fourth quarter of this year. The entire Company is working diligently to complete the remaining activities and close out the study. We believe the Abili-T trial results could significantly impact the lives of those suffering with multiple sclerosis. Secondary progressive MS is a serious disease for which currently, there are no treatment options. We believe Tcelna has the potential to become the first safe and effective treatment for secondary progressive MS patients."

"If Tcelna is proven safe and effective, we believe it could become the therapy of choice for patients with the progressive form of multiple sclerosis and, possibly, enable us to enter what we estimate to be a roughly $7 billion overall market," continued Warma. "Additionally, with positive results in the Abili-T study, we could be positioned for a streamlined path to a Phase III pivotal trial in secondary progressive MS. This would involve working closely with Merck Serono, our potential partner for Tcelna. In 2013, we signed an option and license agreement with Merck Serono, one of the top MS companies in the world. With positive Phase II data, we believe Merck Serono would exercise their option and advance Tcelna into a Phase III trial and through clinical development in MS."

Business Highlights

Clinical Efforts

The Phase 2b Abili-T trial of Tcelna® (imilecleucel-T) in secondary progressive multiple sclerosis (SPMS) continued to advance in the second quarter. Approximately 99% of all patient visits have now been completed and top-line data is expected in early fourth quarter of 2016. The Abili-T clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Tcelna in subjects with SPMS and is being conducted at approximately 35 leading clinical sites in the U.S. and Canada. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Tcelna in SPMS.

Corporate Activities

In April, Neil K. Warma, Opexa's President and Chief Executive Officer, was invited to present at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, in Vatican City. Mr. Warma was among the world's leading cell therapy scientists, physicians, patients, ethicists and leaders of faith, government and philanthropists discussing the latest cellular therapy breakthroughs and the hope they provide for the future treatment of disease. Mr. Warma's presentation was entitled, "Can T-cells be Used to Treat Neuromyelitis Optica (NMO) and Other Autoimmune Disorders?"

In May, Neil K. Warma, Opexa's President and Chief Executive Officer, was an invited speaker at the U.S. China Innovation and Investment Summit in Houston, Texas. The summit was organized in part by the Ministry of Science and Technology of the People's Republic of China, the State of Texas Governor's Office and the City of Houston Mayor's Office.

Financial Results for the Quarter Ended June 30, 2016

Cash position: Cash and cash equivalents were $7,847,360 as of June 30, 2016, compared to $12,583,764 as of December 31, 2015.

R & D Expense: Research and development expenses were $1,814,940 for the three months ended June 30, 2016, compared to $2,795,858 for the three months ended June 30, 2015. The decrease in expenses is primarily due to cost reductions in connection with the winding down of the clinical trial of Tcelna in SPMS, especially a reduction in milestone payments to Opexa's contract research organization as well as a reduction in site expenses. There was also a decrease in the procurement and use of supplies for product manufacturing and development which was partially offset by an increase in supplies and legal expenses related to the NMO study development.

G & A Expense: General and administrative expenses were $953,582 for the three months ended June 30, 2016, compared with $1,345,624 for the three months ended June 30, 2015.

Net loss: Net loss reported for the three months ended June 30, 2016 was approximately $2.1 million, or $0.30 loss per share (basic and diluted), compared with a net loss of approximately $3.5 million or $0.56 loss per share (basic and diluted) for the three months ended June 30, 2015.

Financial Guidance

Based on the current activities of the Company and projected burn, Opexa believes it has sufficient liquidity to support our current clinical activities for the Abili-T trial of Tcelna in SPMS, to continue planned preclinical development activities for OPX-212 in NMO, and for general operations to sustain the Company and support such activities into the first quarter of 2017. Opexa expects top-line data for the Abili-T trial to be available early in the fourth quarter of 2016, and thus believes it has sufficient resources to complete the trial.

For additional information please see Opexa's Quarterly Report on Form 10-Q filed today with the SEC.

Conference Call and Webcast Details

The Company will host a conference call and webcast today at 4:30 p.m. ET to provide an update on the Company and discuss second quarter 2016 financial results. To access the conference call, please dial 201-689-8040 or toll free 877-407-8133 five minutes prior to the start time. The conference ID number is 13642247.

A live webcast of the call can also be accessed here or via the webcast link on the Investor Relations page of Opexa's website (www.opexatherapeutics.com). An archive of the webcast will be available on the Company's website until November 11, 2016.

There will be a brief Question & Answer session following management commentary.

About OpexaOpexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase 2b clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.

Cautionary Statement Relating to Forward-Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995

Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as Tcelna® and OPX-212 as well as the sufficiency of our resources, constitute forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation our ability to raise additional capital to continue our development programs, our ability to successfully develop potential products such as Tcelna and OPX-212, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna and OPX-212), the ability of any of our potential products (such as Tcelna), assuming approval by applicable regulatory authorities (such as the Food and Drug Administration), to achieve commercial success, as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2015 and our Quarterly Reports on Form 10-Q. All forward-looking statements contained in this release speak only as of the date on which they were first made by us, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after such date.